Angiodynamics (ANGO) Enterprise Value (2016 - 2025)
Angiodynamics (ANGO) has disclosed Enterprise Value for 16 consecutive years, with -$41.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Enterprise Value rose 23.02% year-over-year to -$41.6 million, compared with a TTM value of -$41.6 million through Nov 2025, up 23.02%, and an annual FY2025 reading of -$55.9 million, up 26.51% over the prior year.
- Enterprise Value was -$41.6 million for Q4 2025 at Angiodynamics, down from -$38.8 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$23.9 million in Q1 2022 and bottomed at -$78.5 million in Q1 2024.
- Average Enterprise Value over 5 years is -$45.9 million, with a median of -$44.7 million recorded in 2023.
- The sharpest move saw Enterprise Value skyrocketed 56.14% in 2022, then crashed 160.54% in 2024.
- Year by year, Enterprise Value stood at -$34.3 million in 2021, then rose by 12.93% to -$29.9 million in 2022, then crashed by 103.96% to -$60.9 million in 2023, then increased by 11.18% to -$54.1 million in 2024, then increased by 23.02% to -$41.6 million in 2025.
- Business Quant data shows Enterprise Value for ANGO at -$41.6 million in Q4 2025, -$38.8 million in Q3 2025, and -$55.9 million in Q2 2025.